About Us

As part of the Konica Minolta family, we uniquely unite genetics, imaging and pathology to help pharmaceutical developers and clinicians realize more precise, individualized applications that enable more prescriptive, proactive and preventive care. We bring together the most novel and diverse set of data from genes, proteins, cells and tissues with sophisticated analytics and world-leading scientific and medical expertise.

Leadership Team

Tsuyoshi Mitsuhashi

President, Konica Minolta Precision Medicine Japan, Inc.

Tsuyoshi Mitsuhashi was appointed President of Konica Minolta Precision Medicine Japan, Inc. in October 2019. He joined Konishiroku Photo Industry Co., Ltd., which later became Konica Corporation, in 1987. After engaging in the development of medical X-ray film and dry film, he led the development of an Ultrasound system, which was a new business field for the company.

Having served as General Manager of the Healthcare Business Planning Division of Konica Minolta, Inc. (Konica Minolta), Mitsuhashi played a pivotal role in the launch of the Precision Medicine Business in 2017, with a focus on corporate planning and M&A, among other areas.

Taking advantage of his many years of knowledge and experience in the fields of chemistry, imaging, and medical care, he has been working on technical developments and business growth based on Konica Minolta's strengths and innovation in precision medicine and is also in charge of the Precision Medicine Business Unit at Konica Minolta.

Aaron Elliott, PH.D.

Chief Executive Officer, Konica Minolta Precision Medicine

Dr. Aaron Elliott is responsible for driving execution across all Konica Minolta Precision Medicine (KMPM) business units, which include Ambry Genetics, Invicro and KMPM-Japan.

Prior to his role as CEO of KMPM, Dr. Elliott was at Ambry Genetics leading the company through 13 years of trailblazing milestones. He joined Ambry in 2008 in the research and development department working closely on the development of comprehensive molecular diagnostic tests. An innovator in complex genetic testing, Dr. Elliott has been involved in the conception and implementation of many of the diagnostic industry first to market tests and technologies including the first commercial NGS assay, CLIA/CAP Exome test and hereditary cancer panels among others.

Dr. Elliott has helped guide the company through extreme periods of growth, including the acquisition by Konica Minolta. Over the years he held many leadership positions at Ambry, including Director of Genomic Services, Chief Operating Officer, Chief Scientific Officer, and and Chief Executive Officer.

Dr. Elliott began his career as a Postdoctoral Fellow at the Novartis Institute of Functional Genomics in San Diego, where he conducted research on potential drug targets for chemotherapeutic resistance and tumor formation. As part of this research, Dr. Elliott helped in identifying the first mitochondrial ABC transporter in cancer cells, which are responsible for multi-drug resistance in many solid tumors.

A graduate of Franklin and Marshall College, Dr. Elliott conducted his Ph.D. Genetics training at Thomas Jefferson University and The Johns Hopkins University School of Medicine.

Dr. Ken Bloom

CMO, Advanced Pathology & Genomic Services

Dr. Bloom brings more than 30 years of clinical and business experience in pathology, oncology, telemedicine, and bioinformatics. His role will be to help expand, strengthen and commercialize the full-suite of precision medicine capabilities offered within the pathology and genomics markets for Invicro and Ambry Genetics.

Previously, Dr. Bloom was President and Head of Oncology & Immunotherapy for Human Longevity Inc., where his team developed and commercialized an industry leading cancer exome product and commercialized a technique for validating neoantigens predicted from sequencing. Dr. Bloom was also instrumental to the business strategy that evolved Clarient from a start-up to the acquisition by GE Healthcare.

Prior to his industry experience, Dr. Bloom spent 15 years within the academic field holding various appointed positions including Director of Laboratory Operations and Chief Information Officer of the Rush Cancer Institute, Clinical Professor of Pathology at University of Southern California, Keck School of Medicine; and Associate Professor of Pathology at Rush Medical College. Dr. Bloom received his MD from Rush Medical College and his BA from Grinnell College.

Matthew Silva, PhD

CEO, Invicro

Dr. Matthew Silva serves as Chief Executive Officer of Invicro, backed by 20 years of diverse technical and management experience, and is responsible for the strategic direction and tactical performance of the business. Dr. Silva has been with Invicro for 7 years in various executive positions, including leading Scientific and Medical Services. Prior to Invicro, Dr. Silva was Senior Director of Translational Biology at Vertex Pharmaceuticals, where he ran the in vivo imaging and histopathology groups supporting discovery and clinical. Previously, Dr. Silva led groups at Amgen, Millennium and Takeda Pharmaceuticals. He holds a Ph.D. and M.S. in Biomedical Engineering from Worcester Polytechnic Institute and a B.S. in Biomedical Engineering from Boston University.

Scientific Advisory Board Members

David Rimm, MD, PhD

Professor, Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine

Dr. David Rimm is a Professor in the Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine. He is the Director of Yale Pathology Tissue Services. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is boarded in Anatomic and Cytopatholgy. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative methods, with projects related to predicting response to both targeted and immune- therapy in cancer and standardization of those assays for CLIA labs. His lab is involved in testing new high-plex methods including imaging mass cytometry (Fluidigm) and digital spatial profiling (NanoString) He also has supported projects related to rapid, low cost diagnostic tests and direct tissue imaging. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biopharma. He also serves on the CAP Immunohistochemistry committee and multiple scientific advisory boards for biotech and pharma. He is an author of over 350 peer-reviewed papers and 8 patents.

Howard I. Scher

Co-Chair, Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative

Co-Chair, Center for Mechanism Based Therapy; Head of the Biomarker Development Initiative; Member and Attending Physician, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), Professor of Medicine at the Weill Cornell Medical College, and the D. Wayne Calloway Chair in Urologic Oncology. Dr. Scher’s research is focused on the codevelopment of targeted therapies and biomarkers such as circulating tumor cells (CTCs) which can be used to guide treatment selection for the individual patient and improve the way drugs are evaluated in the clinic, accelerating regulatory approvals. Accordingly, he has led international efforts to standardize the design and analysis of phase II prostate cancer trials (PCWG2, PCWG3) and helped elucidate key molecular and genetic features of prostate cancer, translating these insights into the clinic by leading early phase and phase III registration trials of abiraterone acetate and enzalutamide which are now FDA approved. Dr. Scher serves as the principal investigator of the NIH Specialized Program of Research Excellence (SPORE) in Prostate Cancer at MSKCC and the Department of Defense-sponsored Prostate Cancer Clinical Trials Consortium (PCCTC), and has received the 2015 AACR Team Science Award for his multidisciplinary work developing AR inhibitors. Most recently Dr. Scher was elected to the Association of American Physicians and named a Fellow of the American Society of Clinical Oncology (ASCO).